APO Research
Talk to an analyst

APO RESEARCH · REPORT

HIV and AIDS Vaccine

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global HIV and AIDS Vaccine Industry Growth and Trends Forecast to 2032

27 December 202594 pages

Choose your research edition.

Industry ResearchHIV and AIDS Vaccine Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal HIV and AIDS Vaccine Industry Growth and Trends Forecast to 203294 pages · $3,450 USDMarket StructureGlobal HIV and AIDS Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal HIV and AIDS Vaccine Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal HIV and AIDS Vaccine Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global HIV and AIDS Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for HIV and AIDS Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for HIV and AIDS Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for HIV and AIDS Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of HIV and AIDS Vaccine include HKUMed, Sanofi-Pasteur, Johnson and Johnson (Janssen), IAVI, Uvax Bio and AELIX Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global HIV and AIDS Vaccine market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The HIV and AIDS Vaccine market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global HIV and AIDS Vaccine market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to HIV and AIDS Vaccine.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global HIV and AIDS Vaccine market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

HIV and AIDS Vaccine Market by Company

HKUMed

Sanofi-Pasteur

Johnson and Johnson (Janssen)

IAVI

Uvax Bio

AELIX Therapeutics

HIV and AIDS Vaccine Segment by Type

Preventive Vaccine

Therapeutic Vaccine

HIV and AIDS Vaccine Segment by Application

Viral Vector Vaccines

Nucleic Acid Vaccines (including mRNA Vaccines)

Recombinant Protein Vaccines

Other Vaccines

HIV and AIDS Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global HIV and AIDS Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of HIV and AIDS Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of HIV and AIDS Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of HIV and AIDS Vaccine manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of HIV and AIDS Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Preventive Vaccine Table 2. Major Company of Therapeutic Vaccine Table 3. Global HIV and AIDS Vaccine Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global HIV and AIDS Vaccine Sales by Type (2021-2026) & (K Units) Table 5. Global HIV and AIDS Vaccine Sales Market Share in Volume by Type (2021-2026) Table 6. Global HIV and AIDS Vaccine Sales by Type (2021-2026) & (US$ Million) Table 7. Global HIV and AIDS Vaccine Sales Market Share in Value by Type (2021-2026) Table 8. Global HIV and AIDS Vaccine Price by Type (2021-2026) & (US$/Unit) Table 9. Global HIV and AIDS Vaccine Sales by Type (2027-2032) & (K Units) Table 10. Global HIV and AIDS Vaccine Sales Market Share in Volume by Type (2027-2032) Table 11. Global HIV and AIDS Vaccine Sales by Type (2027-2032) & (US$ Million) Table 12. Global HIV and AIDS Vaccine Sales Market Share in Value by Type (2027-2032) Table 13. Global HIV and AIDS Vaccine Price by Type (2027-2032) & (US$/Unit) Table 14. North America HIV and AIDS Vaccine Sales by Type (2021-2026) & (K Units) Table 15. North America HIV and AIDS Vaccine Sales by Type (2021-2026) & (US$ Million) Table 16. Europe HIV and AIDS Vaccine Sales by Type (2021-2026) & (K Units) Table 17. Europe HIV and AIDS Vaccine Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific HIV and AIDS Vaccine Sales by Type (2021-2026) & (K Units) Table 19. Asia-Pacific HIV and AIDS Vaccine Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America HIV and AIDS Vaccine Sales by Type (2021-2026) & (K Units) Table 21. Latin America HIV and AIDS Vaccine Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa HIV and AIDS Vaccine Sales by Type (2021-2026) & (K Units) Table 23. Middle East and Africa HIV and AIDS Vaccine Sales by Type (2021-2026) & (US$ Million) Table 24. HIV and AIDS Vaccine Industry Trends Table 25. HIV and AIDS Vaccine Industry Drivers Table 26. HIV and AIDS Vaccine Industry Opportunities and Challenges Table 27. HIV and AIDS Vaccine Industry Restraints Table 28. Global HIV and AIDS Vaccine Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global HIV and AIDS Vaccine Revenue Market Share by Company (2021-2026) Table 30. Global HIV and AIDS Vaccine Sales by Company (2021-2026) & (K Units) Table 31. Global HIV and AIDS Vaccine Sales Share by Company (2021-2026) Table 32. Global HIV and AIDS Vaccine Market Price by Company (2021-2026) & (US$/Unit) Table 33. Global HIV and AIDS Vaccine Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global HIV and AIDS Vaccine Major Company Production Sites and Headquarters Table 35. Global HIV and AIDS Vaccine Company, Product Type & Application Table 36. Global HIV and AIDS Vaccine Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global HIV and AIDS Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global HIV and AIDS Vaccine Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global HIV and AIDS Vaccine Sales by Region (2021-2026) & (K Units) Table 41. Global HIV and AIDS Vaccine Sales Market Share in Volume by Region (2021-2026) Table 42. Global HIV and AIDS Vaccine Sales by Region (2021-2026) & (US$ Million) Table 43. Global HIV and AIDS Vaccine Sales Market Share in Value by Region (2021-2026) Table 44. Global HIV and AIDS Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 45. Global HIV and AIDS Vaccine Sales by Region (2027-2032) & (K Units) Table 46. Global HIV and AIDS Vaccine Sales Market Share in Volume by Region (2027-2032) Table 47. Global HIV and AIDS Vaccine Sales by Region (2027-2032) & (US$ Million) Table 48. Global HIV and AIDS Vaccine Sales Market Share in Value by Region (2027-2032) Table 49. Global HIV and AIDS Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 50. Global HIV and AIDS Vaccine Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global HIV and AIDS Vaccine Sales by Application (2021-2026) & (K Units) Table 52. Global HIV and AIDS Vaccine Sales Market Share in Volume by Application (2021-2026) Table 53. Global HIV and AIDS Vaccine Sales by Application (2021-2026) & (US$ Million) Table 54. Global HIV and AIDS Vaccine Sales Market Share in Value by Application (2021-2026) Table 55. Global HIV and AIDS Vaccine Price by Application (2021-2026) & (US$/Unit) Table 56. Global HIV and AIDS Vaccine Sales by Application (2027-2032) & (K Units) Table 57. Global HIV and AIDS Vaccine Sales Market Share in Volume by Application (2027-2032) Table 58. Global HIV and AIDS Vaccine Sales by Application (2027-2032) & (US$ Million) Table 59. Global HIV and AIDS Vaccine Sales Market Share in Value by Application (2027-2032) Table 60. Global HIV and AIDS Vaccine Price by Application (2027-2032) & (US$/Unit) Table 61. North America HIV and AIDS Vaccine Sales by Application (2021-2026) & (K Units) Table 62. North America HIV and AIDS Vaccine Sales by Application (2021-2026) & (US$ Million) Table 63. Europe HIV and AIDS Vaccine Sales by Application (2021-2026) & (K Units) Table 64. Europe HIV and AIDS Vaccine Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific HIV and AIDS Vaccine Sales by Application (2021-2026) & (K Units) Table 66. Asia-Pacific HIV and AIDS Vaccine Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America HIV and AIDS Vaccine Sales by Application (2021-2026) & (K Units) Table 68. Latin America HIV and AIDS Vaccine Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa HIV and AIDS Vaccine Sales by Application (2021-2026) & (K Units) Table 70. Middle East and Africa HIV and AIDS Vaccine Sales by Application (2021-2026) & (US$ Million) Table 71. HKUMed Company Information Table 72. HKUMed Business Overview Table 73. HKUMed HIV and AIDS Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. HKUMed HIV and AIDS Vaccine Product Portfolio Table 75. HKUMed Recent Development Table 76. Sanofi-Pasteur Company Information Table 77. Sanofi-Pasteur Business Overview Table 78. Sanofi-Pasteur HIV and AIDS Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Sanofi-Pasteur HIV and AIDS Vaccine Product Portfolio Table 80. Sanofi-Pasteur Recent Development Table 81. Johnson and Johnson (Janssen) Company Information Table 82. Johnson and Johnson (Janssen) Business Overview Table 83. Johnson and Johnson (Janssen) HIV and AIDS Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Johnson and Johnson (Janssen) HIV and AIDS Vaccine Product Portfolio Table 85. Johnson and Johnson (Janssen) Recent Development Table 86. IAVI Company Information Table 87. IAVI Business Overview Table 88. IAVI HIV and AIDS Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. IAVI HIV and AIDS Vaccine Product Portfolio Table 90. IAVI Recent Development Table 91. Uvax Bio Company Information Table 92. Uvax Bio Business Overview Table 93. Uvax Bio HIV and AIDS Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Uvax Bio HIV and AIDS Vaccine Product Portfolio Table 95. Uvax Bio Recent Development Table 96. AELIX Therapeutics Company Information Table 97. AELIX Therapeutics Business Overview Table 98. AELIX Therapeutics HIV and AIDS Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. AELIX Therapeutics HIV and AIDS Vaccine Product Portfolio Table 100. AELIX Therapeutics Recent Development Table 101. North America HIV and AIDS Vaccine Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 102. North America HIV and AIDS Vaccine Sales by Country (2021-2026) & (K Units) Table 103. North America HIV and AIDS Vaccine Sales Market Share by Country (2021-2026) Table 104. North America HIV and AIDS Vaccine Sales Forecast by Country (2027-2032) & (K Units) Table 105. North America HIV and AIDS Vaccine Sales Market Share Forecast by Country (2027-2032) Table 106. North America HIV and AIDS Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 107. North America HIV and AIDS Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 108. North America HIV and AIDS Vaccine Market Share by Country (2021-2026) Table 109. North America HIV and AIDS Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 110. North America HIV and AIDS Vaccine Market Share Forecast by Country (2027-2032) Table 111. Europe HIV and AIDS Vaccine Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 112. Europe HIV and AIDS Vaccine Sales by Country (2021-2026) & (K Units) Table 113. Europe HIV and AIDS Vaccine Sales Market Share by Country (2021-2026) Table 114. Europe HIV and AIDS Vaccine Sales Forecast by Country (2027-2032) & (K Units) Table 115. Europe HIV and AIDS Vaccine Sales Market Share Forecast by Country (2027-2032) Table 116. Europe HIV and AIDS Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 117. Europe HIV and AIDS Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 118. Europe HIV and AIDS Vaccine Market Share by Country (2021-2026) Table 119. Europe HIV and AIDS Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 120. Europe HIV and AIDS Vaccine Market Share Forecast by Country (2027-2032) Table 121. Asia-Pacific HIV and AIDS Vaccine Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 122. Asia-Pacific HIV and AIDS Vaccine Sales by Country (2021-2026) & (K Units) Table 123. Asia-Pacific HIV and AIDS Vaccine Sales Market Share by Country (2021-2026) Table 124. Asia-Pacific HIV and AIDS Vaccine Sales Forecast by Country (2027-2032) & (K Units) Table 125. Asia-Pacific HIV and AIDS Vaccine Sales Market Share Forecast by Country (2027-2032) Table 126. Asia-Pacific HIV and AIDS Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 127. Asia-Pacific HIV and AIDS Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 128. Asia-Pacific HIV and AIDS Vaccine Market Share by Country (2021-2026) Table 129. Asia-Pacific HIV and AIDS Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 130. Asia-Pacific HIV and AIDS Vaccine Market Share Forecast by Country (2027-2032) Table 131. Latin America HIV and AIDS Vaccine Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 132. Latin America HIV and AIDS Vaccine Sales by Country (2021-2026) & (K Units) Table 133. Latin America HIV and AIDS Vaccine Sales Market Share by Country (2021-2026) Table 134. Latin America HIV and AIDS Vaccine Sales Forecast by Country (2027-2032) & (K Units) Table 135. Latin America HIV and AIDS Vaccine Sales Market Share Forecast by Country (2027-2032) Table 136. Latin America HIV and AIDS Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 137. Latin America HIV and AIDS Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 138. Latin America HIV and AIDS Vaccine Market Share by Country (2021-2026) Table 139. Latin America HIV and AIDS Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 140. Latin America HIV and AIDS Vaccine Market Share Forecast by Country (2027-2032) Table 141. Middle East and Africa HIV and AIDS Vaccine Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 142. Middle East and Africa HIV and AIDS Vaccine Sales by Country (2021-2026) & (K Units) Table 143. Middle East and Africa HIV and AIDS Vaccine Sales Market Share by Country (2021-2026) Table 144. Middle East and Africa HIV and AIDS Vaccine Sales Forecast by Country (2027-2032) & (K Units) Table 145. Middle East and Africa HIV and AIDS Vaccine Sales Market Share Forecast by Country (2027-2032) Table 146. Middle East and Africa HIV and AIDS Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 147. Middle East and Africa HIV and AIDS Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 148. Middle East and Africa HIV and AIDS Vaccine Market Share by Country (2021-2026) Table 149. Middle East and Africa HIV and AIDS Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 150. Middle East and Africa HIV and AIDS Vaccine Market Share Forecast by Country (2027-2032) Table 151. Key Raw Materials Table 152. Raw Materials Key Suppliers Table 153. HIV and AIDS Vaccine Distributors List Table 154. HIV and AIDS Vaccine Customers List Table 155. Research Programs/Design for This Report Table 156. Authors List of This Report Table 157. Secondary Sources Table 158. Primary Sources List of Figures Figure 1. HIV and AIDS Vaccine Image Figure 2. Global HIV and AIDS Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global HIV and AIDS Vaccine Market Size (2021-2032) & (US$ Million) Figure 4. Global HIV and AIDS Vaccine Sales (2021-2032) & (K Units) Figure 5. Preventive Vaccine Image Figure 6. Global Preventive Vaccine Sales YoY Growth (2021-2032) & (K Units) Figure 7. Therapeutic Vaccine Image Figure 8. Global Therapeutic Vaccine Sales YoY Growth (2021-2032) & (K Units) Figure 9. Global HIV and AIDS Vaccine Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global HIV and AIDS Vaccine Market Share by Type 2025 VS 2032 Figure 11. North America HIV and AIDS Vaccine Sales Market Share in Volume by Type in 2025 Figure 12. North America HIV and AIDS Vaccine Sales Market Share in Value by Type in 2025 Figure 13. Europe HIV and AIDS Vaccine Sales Market Share in Volume by Type in 2025 Figure 14. Europe HIV and AIDS Vaccine Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific HIV and AIDS Vaccine Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific HIV and AIDS Vaccine Sales Market Share in Value by Type in 2025 Figure 17. Latin America HIV and AIDS Vaccine Sales Market Share in Volume by Type in 2025 Figure 18. Latin America HIV and AIDS Vaccine Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa HIV and AIDS Vaccine Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa HIV and AIDS Vaccine Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 HIV and AIDS Vaccine Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Viral Vector Vaccines Image Figure 24. Global Viral Vector Vaccines Sales YoY Growth (2021-2032) & (K Units) Figure 25. Nucleic Acid Vaccines (including mRNA Vaccines) Image Figure 26. Global Nucleic Acid Vaccines (including mRNA Vaccines) Sales YoY Growth (2021-2032) & (K Units) Figure 27. Recombinant Protein Vaccines Image Figure 28. Global Recombinant Protein Vaccines Sales YoY Growth (2021-2032) & (K Units) Figure 29. Other Vaccines Image Figure 30. Global Other Vaccines Sales YoY Growth (2021-2032) & (K Units) Figure 31. Global HIV and AIDS Vaccine Market Size Overview by Application (2021-2032) & (US$ Million) Figure 32. Global HIV and AIDS Vaccine Market Share by Application 2025 VS 2032 Figure 33. North America HIV and AIDS Vaccine Sales Market Share in Volume by Application in 2025 Figure 34. North America HIV and AIDS Vaccine Sales Market Share in Value by Application in 2025 Figure 35. Europe HIV and AIDS Vaccine Sales Market Share in Volume by Application in 2025 Figure 36. Europe HIV and AIDS Vaccine Sales Market Share in Value by Application in 2025 Figure 37. Asia-Pacific HIV and AIDS Vaccine Sales Market Share in Volume by Application in 2025 Figure 38. Asia-Pacific HIV and AIDS Vaccine Sales Market Share in Value by Application in 2025 Figure 39. Latin America HIV and AIDS Vaccine Sales Market Share in Volume by Application in 2025 Figure 40. Latin America HIV and AIDS Vaccine Sales Market Share in Value by Application in 2025 Figure 41. Middle East and Africa HIV and AIDS Vaccine Sales Market Share in Volume by Application in 2025 Figure 42. Middle East and Africa HIV and AIDS Vaccine Sales Market Share in Value by Application in 2025 Figure 43. North America HIV and AIDS Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 44. North America HIV and AIDS Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. North America HIV and AIDS Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. North America HIV and AIDS Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe HIV and AIDS Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 48. Europe HIV and AIDS Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe HIV and AIDS Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Europe HIV and AIDS Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific HIV and AIDS Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 52. Asia-Pacific HIV and AIDS Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific HIV and AIDS Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Asia-Pacific HIV and AIDS Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America HIV and AIDS Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 56. Latin America HIV and AIDS Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America HIV and AIDS Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Latin America HIV and AIDS Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa HIV and AIDS Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 60. Middle East and Africa HIV and AIDS Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa HIV and AIDS Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Middle East and Africa HIV and AIDS Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. HIV and AIDS Vaccine Value Chain Figure 64. Key Raw Materials Price Figure 65. Manufacturing Cost Structure Figure 66. HIV and AIDS Vaccine Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Preventive Vaccine
  • Therapeutic Vaccine
Applications
  • Viral Vector Vaccines
  • Nucleic Acid Vaccines (including mRNA Vaccines)
  • Recombinant Protein Vaccines
  • Other Vaccines
Companies covered
  • HKUMed
  • Sanofi-Pasteur
  • Johnson and Johnson (Janssen)
  • IAVI
  • Uvax Bio
  • AELIX Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global HIV and AIDS Vaccine Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global HIV and AIDS Vaccine Sales Estimates and Forecasts (2021-2032)
  5. 1.3 HIV and AIDS Vaccine Market by Type
  6. 1.3.1 Preventive Vaccine
  7. 1.3.2 Therapeutic Vaccine
  8. 1.4 Global HIV and AIDS Vaccine Market Size by Type
  9. 1.4.1 Global HIV and AIDS Vaccine Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global HIV and AIDS Vaccine Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global HIV and AIDS Vaccine Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America HIV and AIDS Vaccine Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe HIV and AIDS Vaccine Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific HIV and AIDS Vaccine Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America HIV and AIDS Vaccine Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa HIV and AIDS Vaccine Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 HIV and AIDS Vaccine Industry Trends
  2. 2.2 HIV and AIDS Vaccine Industry Drivers
  3. 2.3 HIV and AIDS Vaccine Industry Opportunities and Challenges
  4. 2.4 HIV and AIDS Vaccine Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by HIV and AIDS Vaccine Revenue (2021-2026)
  2. 3.2 Global Top Players by HIV and AIDS Vaccine Sales (2021-2026)
  3. 3.3 Global Top Players by HIV and AIDS Vaccine Price (2021-2026)
  4. 3.4 Global HIV and AIDS Vaccine Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global HIV and AIDS Vaccine Major Company Production Sites & Headquarters
  6. 3.6 Global HIV and AIDS Vaccine Company, Product Type & Application
  7. 3.7 Global HIV and AIDS Vaccine Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global HIV and AIDS Vaccine Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 HIV and AIDS Vaccine Players Market Share by Revenue in 2025
  11. 3.8.3 2025 HIV and AIDS Vaccine Tier 1, Tier 2, and Tier 3
4 HIV and AIDS Vaccine Regional Status and Outlook
  1. 4.1 Global HIV and AIDS Vaccine Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global HIV and AIDS Vaccine Historic Market Size by Region
  3. 4.2.1 Global HIV and AIDS Vaccine Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global HIV and AIDS Vaccine Sales in Value by Region (2021-2026)
  5. 4.2.3 Global HIV and AIDS Vaccine Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global HIV and AIDS Vaccine Forecasted Market Size by Region
  7. 4.3.1 Global HIV and AIDS Vaccine Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global HIV and AIDS Vaccine Sales in Value by Region (2027-2032)
  9. 4.3.3 Global HIV and AIDS Vaccine Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 HIV and AIDS Vaccine by Application
  1. 5.1 HIV and AIDS Vaccine Market by Application
  2. 5.1.1 Viral Vector Vaccines
  3. 5.1.2 Nucleic Acid Vaccines (including mRNA Vaccines)
  4. 5.1.3 Recombinant Protein Vaccines
  5. 5.1.4 Other Vaccines
  6. 5.2 Global HIV and AIDS Vaccine Market Size by Application
  7. 5.2.1 Global HIV and AIDS Vaccine Market Size Overview by Application (2021-2032)
  8. 5.2.2 Global HIV and AIDS Vaccine Historic Market Size Review by Application (2021-2026)
  9. 5.2.3 Global HIV and AIDS Vaccine Forecasted Market Size by Application (2027-2032)
  10. 5.3 Key Regions Market Size by Application
  11. 5.3.1 North America HIV and AIDS Vaccine Sales Breakdown by Application (2021-2026)
  12. 5.3.2 Europe HIV and AIDS Vaccine Sales Breakdown by Application (2021-2026)
  13. 5.3.3 Asia-Pacific HIV and AIDS Vaccine Sales Breakdown by Application (2021-2026)
  14. 5.3.4 South America HIV and AIDS Vaccine Sales Breakdown by Application (2021-2026)
  15. 5.3.5 Middle East and Africa HIV and AIDS Vaccine Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 HKUMed
  2. 6.1.1 HKUMed Company Information
  3. 6.1.2 HKUMed Business Overview
  4. 6.1.3 HKUMed HIV and AIDS Vaccine Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 HKUMed HIV and AIDS Vaccine Product Portfolio
  6. 6.1.5 HKUMed Recent Developments
  7. 6.2 Sanofi-Pasteur
  8. 6.2.1 Sanofi-Pasteur Company Information
  9. 6.2.2 Sanofi-Pasteur Business Overview
  10. 6.2.3 Sanofi-Pasteur HIV and AIDS Vaccine Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Sanofi-Pasteur HIV and AIDS Vaccine Product Portfolio
  12. 6.2.5 Sanofi-Pasteur Recent Developments
  13. 6.3 Johnson and Johnson (Janssen)
  14. 6.3.1 Johnson and Johnson (Janssen) Company Information
  15. 6.3.2 Johnson and Johnson (Janssen) Business Overview
  16. 6.3.3 Johnson and Johnson (Janssen) HIV and AIDS Vaccine Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Johnson and Johnson (Janssen) HIV and AIDS Vaccine Product Portfolio
  18. 6.3.5 Johnson and Johnson (Janssen) Recent Developments
  19. 6.4 IAVI
  20. 6.4.1 IAVI Company Information
  21. 6.4.2 IAVI Business Overview
  22. 6.4.3 IAVI HIV and AIDS Vaccine Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 IAVI HIV and AIDS Vaccine Product Portfolio
  24. 6.4.5 IAVI Recent Developments
  25. 6.5 Uvax Bio
  26. 6.5.1 Uvax Bio Company Information
  27. 6.5.2 Uvax Bio Business Overview
  28. 6.5.3 Uvax Bio HIV and AIDS Vaccine Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Uvax Bio HIV and AIDS Vaccine Product Portfolio
  30. 6.5.5 Uvax Bio Recent Developments
  31. 6.6 AELIX Therapeutics
  32. 6.6.1 AELIX Therapeutics Company Information
  33. 6.6.2 AELIX Therapeutics Business Overview
  34. 6.6.3 AELIX Therapeutics HIV and AIDS Vaccine Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 AELIX Therapeutics HIV and AIDS Vaccine Product Portfolio
  36. 6.6.5 AELIX Therapeutics Recent Developments
7 North America by Country
  1. 7.1 North America HIV and AIDS Vaccine Sales by Country
  2. 7.1.1 North America HIV and AIDS Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America HIV and AIDS Vaccine Sales by Country (2021-2026)
  4. 7.1.3 North America HIV and AIDS Vaccine Sales Forecast by Country (2027-2032)
  5. 7.2 North America HIV and AIDS Vaccine Market Size by Country
  6. 7.2.1 North America HIV and AIDS Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America HIV and AIDS Vaccine Market Size by Country (2021-2026)
  8. 7.2.3 North America HIV and AIDS Vaccine Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe HIV and AIDS Vaccine Sales by Country
  2. 8.1.1 Europe HIV and AIDS Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe HIV and AIDS Vaccine Sales by Country (2021-2026)
  4. 8.1.3 Europe HIV and AIDS Vaccine Sales Forecast by Country (2027-2032)
  5. 8.2 Europe HIV and AIDS Vaccine Market Size by Country
  6. 8.2.1 Europe HIV and AIDS Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe HIV and AIDS Vaccine Market Size by Country (2021-2026)
  8. 8.2.3 Europe HIV and AIDS Vaccine Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific HIV and AIDS Vaccine Sales by Country
  2. 9.1.1 Asia-Pacific HIV and AIDS Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific HIV and AIDS Vaccine Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific HIV and AIDS Vaccine Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific HIV and AIDS Vaccine Market Size by Country
  6. 9.2.1 Asia-Pacific HIV and AIDS Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific HIV and AIDS Vaccine Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific HIV and AIDS Vaccine Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America HIV and AIDS Vaccine Sales by Country
  2. 10.1.1 South America HIV and AIDS Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America HIV and AIDS Vaccine Sales by Country (2021-2026)
  4. 10.1.3 South America HIV and AIDS Vaccine Sales Forecast by Country (2027-2032)
  5. 10.2 South America HIV and AIDS Vaccine Market Size by Country
  6. 10.2.1 South America HIV and AIDS Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America HIV and AIDS Vaccine Market Size by Country (2021-2026)
  8. 10.2.3 South America HIV and AIDS Vaccine Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa HIV and AIDS Vaccine Sales by Country
  2. 11.1.1 Middle East and Africa HIV and AIDS Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa HIV and AIDS Vaccine Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa HIV and AIDS Vaccine Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa HIV and AIDS Vaccine Market Size by Country
  6. 11.2.1 Middle East and Africa HIV and AIDS Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa HIV and AIDS Vaccine Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa HIV and AIDS Vaccine Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 HIV and AIDS Vaccine Value Chain Analysis
  2. 12.1.1 HIV and AIDS Vaccine Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 HIV and AIDS Vaccine Production Mode & Process
  7. 12.2 HIV and AIDS Vaccine Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 HIV and AIDS Vaccine Distributors
  10. 12.2.3 HIV and AIDS Vaccine Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst